[go: up one dir, main page]

EE200300092A - EDb-fibronektiinidomeeni retseptor - Google Patents

EDb-fibronektiinidomeeni retseptor

Info

Publication number
EE200300092A
EE200300092A EEP200300092A EEP200300092A EE200300092A EE 200300092 A EE200300092 A EE 200300092A EE P200300092 A EEP200300092 A EE P200300092A EE P200300092 A EEP200300092 A EE P200300092A EE 200300092 A EE200300092 A EE 200300092A
Authority
EE
Estonia
Prior art keywords
sub
edb
domain receptor
fibronectin domain
fibronectin domains
Prior art date
Application number
EEP200300092A
Other languages
English (en)
Estonian (et)
Inventor
Redlitz Alexander
Koppitz Marcus
Egner Ursula
Bahr Inke
Menrad Andreas
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10045803A external-priority patent/DE10045803A1/de
Priority claimed from DE2001123133 external-priority patent/DE10123133A1/de
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of EE200300092A publication Critical patent/EE200300092A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EEP200300092A 2000-09-07 2001-08-30 EDb-fibronektiinidomeeni retseptor EE200300092A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10045803A DE10045803A1 (de) 2000-09-07 2000-09-07 Rezeptor der EDb Fibronektin-Domäne
DE2001123133 DE10123133A1 (de) 2001-05-02 2001-05-02 Rezeptor der ED¶b¶-Fibronektin-Domäne (II)
PCT/EP2001/010016 WO2002020563A2 (de) 2000-09-07 2001-08-30 REZEPTOR DER EDb-FIBRONEKTIN-DOMÄNE (II)

Publications (1)

Publication Number Publication Date
EE200300092A true EE200300092A (et) 2005-06-15

Family

ID=26007070

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300092A EE200300092A (et) 2000-09-07 2001-08-30 EDb-fibronektiinidomeeni retseptor

Country Status (24)

Country Link
US (3) US20020197700A1 (no)
EP (1) EP1381629B1 (no)
JP (1) JP2004529848A (no)
KR (1) KR20030045056A (no)
CN (1) CN1246333C (no)
AT (1) ATE407951T1 (no)
AU (1) AU1218202A (no)
BG (1) BG107614A (no)
BR (1) BR0113737A (no)
CA (1) CA2421783A1 (no)
DE (1) DE50114321D1 (no)
EE (1) EE200300092A (no)
ES (1) ES2312478T3 (no)
HK (1) HK1064683A1 (no)
HR (1) HRP20030263A2 (no)
HU (1) HUP0300935A3 (no)
IL (1) IL154778A0 (no)
NO (1) NO20031033L (no)
NZ (1) NZ524342A (no)
PL (1) PL364358A1 (no)
RU (1) RU2280254C2 (no)
SK (1) SK2882003A3 (no)
WO (1) WO2002020563A2 (no)
YU (1) YU17503A (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062800A1 (en) 2000-02-24 2001-08-30 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US7785591B2 (en) * 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP1945767B1 (de) 2005-11-09 2010-04-07 MorphoSys AG Identifizierung und charakterisierung von funktionsblockierenden anti-ed-b-fibronektin antikörpern
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
ES2402171T3 (es) 2007-04-02 2013-04-29 Philogen S.P.A. El antígeno ED-A del fibrinógeno está asociado con la neovasculatura de las metástasis tumorales
US10202442B2 (en) 2007-07-25 2019-02-12 Philogen S.P.A. Antigen associated with lung cancers and lymphomas
HUE037036T2 (hu) * 2007-10-30 2018-08-28 Philogen Spa Rheumatoid arthritisszel kapcsolatos antigén
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
US8679488B2 (en) 2009-08-05 2014-03-25 Philogen S.P.A. Targeting of bone marrow neovasculature
SG11201502404WA (en) 2012-10-03 2015-05-28 Philogen Spa Antigens associated with inflammatory bowel disease
EP3689903A4 (en) 2017-09-30 2022-01-12 Hefei Lifeon Pharmaceutical Co. Ltd. FIBRONECTIN B DOMAIN BINDING PROTEIN

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341223A (en) * 1981-02-04 1982-07-27 Lutz Lauralee A Fluoresceable composition and method of determining fluid flow
US4741900A (en) * 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5243029A (en) * 1986-04-09 1993-09-07 Fred Hutchinson Cancer Research Center Oncofetal structure of fibronectin
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US5177015A (en) * 1988-08-12 1993-01-05 Fred Hutchinson Cancer Research Centre Onco-developmentally regulated α-N-acetylgalactosaminyltransferase
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
JP3070763B2 (ja) * 1989-08-09 2000-07-31 ロメッド インコーポレイティド テクネチウムまたはレニウムでの抗体または他のタンパク質の直接放射能標識
US5120830A (en) * 1990-10-25 1992-06-09 Washington University Inhibitory peptides against α-2, β-1 mediated mg++ dependent adhesion of platelets to collagen
US5629291A (en) * 1992-01-31 1997-05-13 La Jolla Cancer Research Foundation Methods of modulating fibronectin extracellular matrix assembly
AU675929B2 (en) * 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5976535A (en) * 1992-06-09 1999-11-02 Neorx Corporation Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
EP0614696A4 (en) * 1992-09-25 1995-04-26 Otsuka Pharma Co Ltd ADSORBENT FOR CELLULAR FIBRONECTIN, SEPARATION AND PURIFICATION OF FIBRONECTIN, AND PURIFICATION OF BLOOD.
JP3339724B2 (ja) * 1992-09-29 2002-10-28 株式会社リコー インクジェット記録方法及びその装置
US5491130A (en) * 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6015897A (en) * 1993-12-07 2000-01-18 Neorx Corporation Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
US5523229A (en) * 1994-03-22 1996-06-04 Trustees Of The University Of Pennsylvania Antibodies specific for oncofetal fibronectin
DE4417865A1 (de) * 1994-05-20 1995-11-23 Behringwerke Ag Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie
US5648485A (en) * 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
DE4445065A1 (de) * 1994-12-07 1996-06-13 Diagnostikforschung Inst Verfahren zur In-vivo-Diagnostik mittels NIR-Strahlung
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US5808146A (en) * 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
GB9610967D0 (en) * 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
US5913884A (en) * 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US5842156A (en) * 1996-11-12 1998-11-24 The United States Of America As Represented By The Secretary Of The Air Force Multirate multiresolution target tracking
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
US6394952B1 (en) * 1998-02-03 2002-05-28 Adeza Biomedical Corporation Point of care diagnostic systems
US6267722B1 (en) * 1998-02-03 2001-07-31 Adeza Biomedical Corporation Point of care diagnostic systems
US6296831B1 (en) * 1998-04-10 2001-10-02 Battelle Memorial Institute Stimulus sensitive gel with radioisotope and methods of making
US5997842A (en) * 1998-04-13 1999-12-07 Light Sciences Limited Partnership Radionuclide excited phosphorescent material for administering PDT
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) * 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US20030176663A1 (en) * 1998-05-11 2003-09-18 Eidgenossische Technische Hochscule Specific binding molecules for scintigraphy
US6630570B1 (en) * 1999-04-09 2003-10-07 Insitut für Diagnostikforschung GmbH Short-chain peptide-dye conjugates as contrast media for optical diagnosis
US6171578B1 (en) * 1999-04-14 2001-01-09 Diatide, Inc. Benzodiazepine derivatives for imaging thrombi
CN101073668A (zh) * 1999-04-28 2007-11-21 德克萨斯大学董事会 用于通过选择性抑制vegf来治疗癌症的组合物和方法
AU2001227837A1 (en) * 2000-01-12 2001-07-24 Light Sciences Corporation Novel treatment for eye disease
US8623373B2 (en) * 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
US6342326B1 (en) * 2000-05-10 2002-01-29 Beckman Coulter, Inc. Synthesis and use of acyl fluorides of cyanine dyes
JP2005505242A (ja) * 2001-03-07 2005-02-24 マンカインド コーポレイション 癌用抗新生血管系調製物
WO2003008537A2 (en) * 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
JP2005523887A (ja) * 2002-01-03 2005-08-11 シエーリング アクチエンゲゼルシャフト 腫瘍の新しい診断および治療方法
AR040956A1 (es) * 2002-07-31 2005-04-27 Schering Ag Nuevos conjugados de efectores, procedimientos para su preparacion y su uso farmaceutico

Also Published As

Publication number Publication date
HK1064683A1 (en) 2005-02-04
WO2002020563A2 (de) 2002-03-14
IL154778A0 (en) 2003-10-31
NZ524342A (en) 2005-09-30
HRP20030263A2 (en) 2005-10-31
CN1246333C (zh) 2006-03-22
HUP0300935A2 (hu) 2003-12-29
JP2004529848A (ja) 2004-09-30
CA2421783A1 (en) 2002-03-14
WO2002020563A3 (de) 2003-10-09
ES2312478T3 (es) 2009-03-01
US20050089941A1 (en) 2005-04-28
EP1381629B1 (de) 2008-09-10
NO20031033L (no) 2003-05-07
AU1218202A (en) 2002-03-22
NO20031033D0 (no) 2003-03-06
RU2280254C2 (ru) 2006-07-20
CN1487953A (zh) 2004-04-07
BR0113737A (pt) 2004-02-25
US20020197700A1 (en) 2002-12-26
YU17503A (sh) 2006-05-25
BG107614A (bg) 2003-12-31
EP1381629A2 (de) 2004-01-21
RU2003109431A (ru) 2005-01-20
DE50114321D1 (de) 2008-10-23
HUP0300935A3 (en) 2005-09-28
ATE407951T1 (de) 2008-09-15
US20050221434A1 (en) 2005-10-06
SK2882003A3 (en) 2003-08-05
KR20030045056A (ko) 2003-06-09
PL364358A1 (en) 2004-12-13

Similar Documents

Publication Publication Date Title
EA200401198A1 (ru) АНТИТЕЛА ПРОТИВ αvβ6
DK1311482T3 (da) Ikke-imidazolaryloxypiperidiner som H3-receptorligander
DK1337518T3 (da) Piperazinylpyrazinforbindelser som antagonister for serotonin-5-HT2-receptoren
TR200300322T2 (tr) Kemokin alıcısını bağlayan heterosiklik bileşikler
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
DK0906426T3 (da) Antistoffer mod ED-B-domænet af fibronektin, deres konstruktion og anvendelser
ATE344254T1 (de) 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren
HRP20040618B1 (hr) Supstituirani 2-tio-3,5-dicijano-4-fenil-6-aminopiridini i njihova upotreba
NO20061412L (no) Terapi av okulaere foretyrrelser
DK1633697T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aryl-butyl-aminforbindelser
UA89017C2 (uk) ЛЮДСЬКЕ АНТИТІЛО, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ЛЮДСЬКИМ TNFSF13b
TR199901575T2 (xx) Vitronektin resept�r antagonistleri.
CY1111194T1 (el) Ενωσεις πιπεριδινυλιου που επιλεκτικα προσδενουν ιντεγρινες
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
EA200200732A1 (ru) Замещенные производные фенилпиперазина, их получение и применение
EA200400454A1 (ru) Мускариновые агонисты
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
DE60139770D1 (de) Hydantoin derivate mit affinität für somatostatin rezeptoren
DK1206452T3 (da) Fremgangsmåde til fremstilling af benzoperhydro-isoindolforbindelser
GB0103045D0 (en) Organic Compounds
DE60319989D1 (de) Diazabicylononan - und decanderivate und ihre verwendung als opioid-rezeptorligande
SE9904660D0 (sv) Novel assays
DE69906101D1 (de) 3-bicycloindole als liganden des 5-ht 1d rezeptors
EA200702197A1 (ru) Противораковая комбинация, содержащая производные замещённого акрилоилдистамицина и антитела, ингибирующие факторы роста или их рецепторы